Eugene F Douglass, Jr.
Affiliations: | 2014 | Yale University, New Haven, CT |
Google:
"Eugene F Douglass, Jr."Mean distance: 8.19 | S | N | B | C | P |
Parents
Sign in to add mentor| Eugene F Douglass | grad student | 1985- | Son of Eugene F Douglass | |
| (Eldest son of Eugene F Douglass) | ||||
| Christopher R. Lambert | grad student | 2007-2008 | Worcester Polytechnic Institute | |
| (Undergraduate and Graduate Student) | ||||
| W Grant McGimpsey | grad student | 2007-2008 | Worcester Polytechnic Institute | |
| David A. Spiegel | grad student | 2014 | Yale | |
| Andrea Califano | post-doc | 2016- | Columbia | |
| Dan Rudolf Littman | post-doc | 2014-2015 | NYU Langone Medical Center | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hu LZ, Douglass E, Turunen M, et al. (2023) Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium. Biorxiv : the Preprint Server For Biology |
| Mundi PS, Dela Cruz FS, Grunn A, et al. (2023) A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies. Cancer Discovery |
| Hughes EA, Zieliński R, Ray AE, et al. (2023) Development of a Novel Tool to Demystify Drug Distribution at Tissue-Blood Barriers. Chembiochem : a European Journal of Chemical Biology. e202200804 |
| Vasciaveo A, Arriaga JM, Nunes de Almeida F, et al. (2022) OncoLoop: A network-based precision cancer medicine framework. Cancer Discovery |
| Douglass EF, Allaway RJ, Szalai B, et al. (2022) A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Reports. Medicine. 3: 100492 |
| Scotto L, Kinahan C, Douglass E, et al. (2021) TARGETING THE T-CELL LYMPHOMA EPIGENOME INDUCES CELL DEATH, CANCER TESTES ANTIGENS, IMMUNE MODULATORY SIGNALING PATHWAYS. Molecular Cancer Therapeutics |
| Douglass EF, Spiegel DA. (2021) Comment on a suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands. The Journal of Biological Chemistry. 296: 100331 |
| Paull EO, Aytes A, Jones SJ, et al. (2021) A modular master regulator landscape controls cancer transcriptional identity. Cell |
| Douglass EF. (2020) Bridging "Big Data" and Mechanistic Insight To Enable Precision Medicine. Chembiochem : a European Journal of Chemical Biology |
| Scotto L, Kinahan C, Casadei B, et al. (2020) Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes, Chromosomes & Cancer |